Kercia Cruz | Agricultural and Biological Sciences | Best Researcher Award

Published on 03/08/202403/08/2024 by Book of Award

Dr. Kercia Cruz | Agricultural and Biological Sciences | Best Researcher Award

Federal University of Bahia | Brazil

Author Profile

Early Academic Pursuits 🎓

Dr. Kercia Cruz began her academic journey with a degree in Biological Sciences from Universidade Federal da Bahia in 2014. She furthered her studies with a master’s in Biotechnology in Health and Investigative Medicine from Fundação Oswaldo Cruz, graduating in 2017. Her research during this period focused on leishmaniasis and the role of macrophages in infection. She then pursued a Ph.D. in Biotechnology in Health and Investigative Medicine at Fundação Oswaldo Cruz, completing it in 2023. Her doctoral research centered on the development of nanomedicines for treating leishmaniasis, particularly focusing on the protein translocator HSP90.

Professional Endeavors 🔬

Dr. Cruz has worked extensively in the field of general biology with a specialization in leishmaniasis and macrophage infections. Her professional experience includes positions at Universidade Federal da Bahia and Centro Universitário SENAI CIMATEC, where she has contributed significantly to research and education. Her roles involved working on projects related to the therapeutic potential of nanoparticles and the molecular mechanisms of leishmaniasis. She has also participated in various internships and short-term research activities across Brazil and Portugal. 🌍

Contributions and Research Focus 🧫

Dr. Cruz’s research primarily focuses on leishmaniasis, particularly the use of nanomedicines and the role of protein translocators like HSP90 in combating infection. She has been involved in several research projects exploring the potential of nanoparticle-based therapies for leishmaniasis and other infectious diseases. Her work also includes studying the molecular and cellular aspects of macrophage interactions with pathogens, contributing to the development of innovative treatment strategies. 🧪

Accolades and Recognition 🏅

Dr. Cruz has received notable recognition for her research contributions. In 2022, she was awarded an honorable mention for her work on polymeric nanoparticles containing amphotericin B at Embrapa. Additionally, she received a commendation in 2020 for her ongoing doctoral thesis from the Program of Postgraduate Studies in Biotechnology in Health and Investigative Medicine at Fiocruz. These accolades highlight her significant impact in her field. 🏆

Impact and Influence 🌟

Dr. Cruz’s research has advanced the understanding of leishmaniasis and the potential of nanomedicines in treating this disease. Her work on nanomedicine and protein translocators has provided valuable insights into innovative treatment approaches, potentially improving patient outcomes and contributing to global health solutions. Her contributions have influenced both academic research and practical applications in biotechnology. 🌐

Legacy and Future Contributions 🚀

Looking forward, Dr. Cruz aims to continue her work on developing novel therapeutic strategies for infectious diseases. Her future research will likely focus on expanding the use of nanomedicines and exploring new avenues in molecular biology to address pressing health challenges. Her dedication to advancing scientific knowledge and improving treatment options ensures that her legacy will continue to benefit the field of biotechnology and beyond.

Publications 📚

📝Intraperitoneal Administration of 17-DMAG as an Effective Treatment against Leishmania braziliensis Infection in BALB/c Mice: A Preclinical Study
- Authors: Kercia P. Cruz, Antonio L. O. A. Petersen, Marina F. Amorim, Alan G. S. F. Pinho, Luana C. Palma, Diana A. S. Dantas, Mariana R. G. Silveira, Carine S. A. Silva, Ana Luiza J. Cordeiro, Izabella G. Oliveira, Gabriella B. Pita, Bianca C. A. Souza, Gilberto C. Bomfim, Cláudia I. Brodskyn, Deborah B. M. Fraga, Isadora S. Lima, Maria B. R. De_Santana, Helena M. P. Teixeira, Juliana P. B. De_Menezes, Washington L. C. Santos
- Journal: Pathogens
- Year: 2024

📝Development and Characterization of PLGA Nanoparticles Containing 17-DMAG, an Hsp90 Inhibitor
- Authors: Kercia P. Cruz, Beatriz F. C. Patricio, Vinícius C. Pires, Marina F. Amorim, Alan G. S. F. Pinho, Helenita C. Quadros, Diana A. S. Dantas, Marcelo H. C. Chaves, Fabio R. Formiga, Helvécio V. A. Rocha, Patrícia S. T. Veras
- Journal: Frontiers in Chemistry
- Year: 2021

📝Microbiologia no cotidiano: proposta de ensino por investigação de baixo custo
- Authors: K. P. Cruz, G. L. Nery, A. A. D. Reboucás, P. R. Dantas-Silva, J. S. Cruz, C. G. S. Andrade, R. M. L. Rahimy
- Journal: Atas de Ciências da Saúde
- Year: 2019

📝In vitro evaluation of the anti-leishmanial activity and toxicity of PK11195
- Authors: C. E. S. Guedes, B. R. S. Dias, A. L. O. A. Petersen, Kercia P. Cruz, N. J. Almeida, D. R. Andrade, J. P. B. Menezes, V. M. Borges, P. S. T. Veras
- Journal: Memórias do Instituto Oswaldo Cruz
- Year: 2018

Fang Wang | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on 03/08/202403/08/2024 by Book of Award

Dr. Fang Wang | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Maastricht University | Netherlands

Author Profile

Scopus

Orcid

Early Academic Pursuits 📚

Dr. Fang Wang's academic journey began with a Bachelor’s degree in Pharmacology from Nanchang University, where she developed an oxidative stress model in LO2 cells to test stress amelioration compounds. She continued her studies with a Master's degree in Cell Biology at the same university, focusing on the role of progesterone adiponectin receptor 7 in reproduction and differences in protein post-translational modifications. Currently, she is pursuing a PhD in Cell Biology at Maastricht University, investigating substrate metabolism in diabetic cardiomyopathy and novel treatments using bioactive components from Traditional Chinese Medicine.

Professional Endeavors 🔬

With over seven years of experience, Dr. Wang has built a strong foundation in preclinical research, drug development, scientific communication, and project management. Her professional career includes internships at Shanghai ChemPartner Co., Ltd. and Jiangxi Zhby Biotech Co. Ltd., where she gained hands-on experience in molecular biology testing and research planning. Her current roles involve significant contributions to research in metabolic disorders and male infertility, with a focus on protein translocation and endosome pH regulation.

Contributions and Research Focus 🌟

Dr. Wang’s research primarily targets the intersection of metabolic disorders and drug development, specifically focusing on diabetic cardiomyopathy and the impact of Traditional Chinese Medicine on cardiac health. Her work includes investigating novel treatment strategies and exploring the mechanisms of substrate metabolism, protein translocation, and endosome pH regulation. Her expertise spans a wide range of molecular and cell biology techniques, including advanced imaging and bioinformatics.

Accolades and Recognition 🏆

Dr. Wang has made notable contributions to the field through her publications and presentations at various conferences. Her research on lipid-induced contractile dysfunction and diabetic cardiomyopathy has been recognized in leading journals and upcoming publications. Her work is highly regarded in the scientific community, reflecting her commitment to advancing healthcare solutions.

Impact and Influence 🌍

Dr. Wang's research has a profound impact on understanding and treating metabolic disorders, particularly in diabetic cardiomyopathy. Her innovative approaches and exploration of traditional medicine offer promising solutions for improving patient outcomes and advancing the field of metabolic disease research. Her contributions are shaping new therapeutic strategies and enhancing the quality of life for patients.

Legacy and Future Contributions 🚀

Dr. Wang's future endeavors are set to further explore and develop cutting-edge healthcare solutions. Her ongoing research aims to refine treatment strategies for metabolic disorders and improve the efficacy of drug development. By integrating advanced techniques and traditional medicine, she is poised to make significant strides in the field, contributing to a healthier future and advancing scientific knowledge.

Publications 📕

📝 Specific Compounds Derived from Traditional Chinese Medicine Ameliorate Lipid-Induced Contractile Dysfunction in Cardiomyocytes
- Authors: Fang Wang, Dietbert Neumann, Dimitrios Kapsokalyvas, Martijn Hoes, Francesco Schianchi, Jan Glatz, Miranda Nabben, Joost J. F. P. Luiken
- Journal: International Journal of Molecular Sciences
- Year: 2024

📝 Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis
- Authors: Shujin Wang, Han YinYing, Ruimin Liu, Hou M, Dietbert Neumann, Jun Zhang, Wang F, Yumeng Li, Zhao X, Francesco Schianchi et al.
- Journal: Circulation Research
- Year: 2024

📝 Progestin and adipoQ receptor 7 (PAQR7) mediate the anti-apoptotic effect of P4 on human granulosa cells and its deficiency reduces ovarian function in female mice
- Authors: Li J, Liu Y, He J, Wu Z, Wang F, Huang J, Zheng L, Luo T
- Journal: Journal of Ovarian Research
- Year: 2024

📝 CD36 as a target for metabolic modulation therapy in cardiac disease
- Authors: Glatz JFC, Wang F, Miranda Nabben, Luiken JJFP
- Journal: Expert Opinion on Therapeutic Targets
- Year: 2021

📝 Diet-induced obesity is associated with altered expression of sperm motility-related genes and testicular post-translational modifications in a mouse model
- Authors: Wang F, Chen H, Chen Y, Cheng Y, Li J, Zheng L, Zeng X, Luo T
- Journal: Theriogenology
- Year: 2020

Ahmet Özdemir | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on 23/07/202423/07/2024 by Book of Award

Prof Dr. Ahmet Özdemir | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Anadolu University | Turkey

Author Profile

Scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Ahmet Özdemir's academic journey began at Salihli Cumhuriyet Elementary School (1978-1983), followed by Salihli 50. Yıl Secondary School (1983-1986) and Salihli High School (1986-1989). His passion for pharmacy led him to Anadolu University Faculty of Pharmacy, where he completed his undergraduate studies (1990-1994). He pursued further education at the Graduate School of Health Sciences, Department of Pharmaceutical Chemistry at Anadolu University, earning a Master's degree (1995-1996) and a Doctor's degree (1996-2004).

Professional Endeavors 💼

Prof. Dr. Özdemir's professional career commenced at Anadolu University as a Research Assistant (1997-2004). He progressed to Research Assistant Doctor (2004-2005), Lecturer (2005-2007), and Assistant Professor Doctor (2007-2010). His dedication and expertise earned him the title of Associate Professor Doctor (2010-2015), and he has been serving as a Professor Doctor since 2015.

Contributions and Research Focus 🔍

Prof. Dr. Özdemir's research is marked by significant contributions to pharmaceutical chemistry. His Master's thesis focused on "The studies on the synthesis, structure elucidations and determination of physicochemical parameters of some 2-substituted-1H-phenantro[9,10-d]imidazole compounds," under the supervision of Prof. Dr. İlhan Işıkdağ. His PhD thesis, supervised by Prof. Dr. Gülhan Turan, investigated the "Synthesis of some 1-[(N,N-disubstituted-thiocarbonylthio)acetyl]-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives and their antifungal, antibacterial activities."

Accolades and Recognition 🏅

Prof. Dr. Özdemir's work has been widely recognized, earning him numerous awards:

Anadolu University Article Performance Award (2014, 2016, 2017, 2018, 2020)
Anadolu University Gold Article Performance Award (2015)
Anadolu University Platinum Article Performance Award (2015)
Anadolu University Academic Success Award (2019)
ISIF'21 Silver Medal for the invention "Targeted Novel Triazolothiadiazine Derivatives for The Treatment of Lung Cancer" (2021)

Impact and Influence 🌟

Prof. Dr. Özdemir's impact extends beyond research. He has held key administrative roles, including Associate Director of Anadolu University Yunus Emre Vocational School (2011-2014) and Vice Academic Director of the Anadolu University Open Education Faculty, Department of Health Administration (2015-present). His mentorship has guided many students, as evidenced by his supervision of numerous master’s and doctoral dissertations.

Legacy and Future Contributions 🚀

Prof. Dr. Özdemir’s legacy is built on his unwavering commitment to advancing pharmaceutical chemistry. His innovative research, administrative leadership, and dedication to education have left an indelible mark on Anadolu University and the broader scientific community. As he continues his work, Prof. Dr. Özdemir is poised to make further groundbreaking contributions that will shape the future of pharmaceutical sciences.

Publications

📜Title: Design, Synthesis, and Biological Evaluation of a New Series of Imidazothiazole-Hydrazone Hybrids as Dual EGFR and Akt Inhibitors for NSCLC Therapy
Authors: Mehlika Dilek Altıntop, İpek Ertorun, Gülşen Akalın Çiftçi, Ahmet Özdemir
Journal: European Journal of Medicinal Chemistry
Year: 2024

📜Title: Design, Synthesis, and In Vivo Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents
Authors: Baramaki, I., Altıntop, M.D., Arslan, R., Hasan, A., Bektaş Türkmen, N.
Journal: ACS Omega
Year: 2024

📜Title: Design, Synthesis, and Evaluation of a New Series of 2-Pyrazolines as Potential Antileukemic Agents
Authors: Altıntop, M.D., Cantürk, Z., Özdemir, A.
Journal: ACS Omega
Year: 2023

📜Title: Design, Synthesis, and Evaluation of a New Series of Hydrazones as Small-Molecule Akt Inhibitors for NSCLC Therapy
Authors: Erdönmez, B., Altıntop, M.D., Akalın Çiftçi, G., Özdemir, A., Ece, A.
Journal: ACS Omega
Year: 2023

📜Title: A New Series of Hydrazones as Small-Molecule Aldose Reductase Inhibitors
Authors: Altıntop, M.D., Demir, Y., Türkeş, C., Beydemir, Ş., Özdemir, A.
Journal: Archiv der Pharmazie
Year: 2023

📜Title: A New Series of Thiazole-Hydrazone Hybrids for Akt-Targeted Therapy of Non-Small Cell Lung Cancer
Authors: Orujova, T., Ece, A., Akalın Çiftçi, G., Özdemir, A., Altıntop, M.D.
Journal: Drug Development Research
Year: 2023

Jiatong Li | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on 23/02/202423/02/2024 by Book of Award

Assist Prof Dr. Jiatong Li | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Shanghai Jiao Tong University School of Medicine | China

Author Profile

Scopus

Early Academic Pursuits

Dr. Jiatong Li began her academic journey with a BA in Clinical Pharmacology at Harbin Medical University, followed by a PhD in Pharmacology under the mentorship of Prof. Bao-Feng Yang. She further honed her skills through an exchange program in Cellular Physiology at Okayama University, Japan.

Professional Endeavors

Joining Shanghai Jiao Tong University School of Medicine, Dr. Li delved into research focusing on novel antitumor therapeutics. She explored pharmacodynamics, drug actions, and underlying mechanisms, contributing significantly to the field.

Contributions and Research Focus

Dr. Li's research primarily revolves around synthesizing and applying six-membered aromatic nitrogen heterocyclic anti-tumor agents. She also investigated the suppression of hepatocellular carcinoma metastasis and cancer stem cell-like properties. Additionally, her work includes solvent-free and catalyst-free direct alkylation of alkenes.

Accolades and Recognition

Dr. Li's impactful research has earned her recognition in prestigious journals, with several publications featuring as cover stories. Her contributions have significantly advanced understanding in the field of pharmacology.

Impact and Influence

Through her research, Dr. Li has made a profound impact on the pharmacological community, shedding light on innovative therapeutic approaches and mechanisms underlying cancer progression.

Legacy and Future Contributions

Dr. Li's legacy lies in her groundbreaking research, which has paved the way for further advancements in antitumor therapeutics. Her future contributions are anticipated to continue shaping the landscape of pharmacology, with a focus on addressing critical challenges in cancer treatment.

Notable Publications

Pancreatic cancer environment: From patient-derived models to single-cell omics 2024

Six-Membered Aromatic Nitrogen Heterocyclic Anti-Tumor Agents: Synthesis and Applications 2023

Aggregation-enabled alkene insertion into carbon–halogen bonds 2023 (1)

Solvent-free and catalyst-free direct alkylation of alkenes 2023 (1)

Trisubstituted alkenes featuring aryl groups: stereoselective synthetic strategies and applications 2023 (3)

Simon Bernard Iloki Assanga | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on 17/02/202417/02/2024 by Book of Award

Prof Dr. Simon Bernard Iloki Assanga | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

University of Sonora | Mexico

Author Profile

Scopus

Orcid

Google Scholar

Early Academic Pursuits

Dr. Simon Bernard Iloki Assanga embarked on his academic journey by obtaining a Bachelor's degree from the Pre-University Institute February 5 in Isle of Youth, Cuba, followed by a Graduate degree in Pharmaceutical Sciences from the University of Havana, Cuba. His academic pursuits culminated with a Doctorate in Pharmaceutical Sciences with a specialty in Immunology from the same institution in 2005.

Professional Endeavors

Dr. Assanga's professional career has been marked by a diverse array of roles, spanning from teaching to research. Noteworthy positions include his tenure as a Subject Teacher at the University of Sonora in Mexico, where he contributed to the Science department's Chemical-Biological sector. Additionally, he served as an Associate Full-Time Research Professor at the Department of Research and Postgraduate Studies in Food (DIPA) at the University of Sonora.

Contributions and Research Focus

Throughout his career, Dr. Assanga has made significant contributions to the field of pharmaceutical sciences and immunology. He has led various research projects, such as investigating the therapeutic potential of natural products for age-related macular degeneration and scaling up pilot plant production for nutraceuticals. His research interests also include exploring the chemical and nutritional composition of medicinal plants and their potential applications in healthcare.

Accolades and Recognition

Dr. Assanga's dedication and contributions have been recognized through numerous awards and honors. Notably, he received recognition for Outstanding Foreign Graduate from the Pharmacy Institute and Food at the University of Havana. He is also a member of prestigious scientific societies like the Society for Redox Biology and Medicine, highlighting his standing in the academic community.

Impact and Influence

Dr. Assanga's research, teaching, and participation in academic events have had a profound impact on the field of pharmaceutical sciences and immunology. His work in elucidating the therapeutic properties of natural products and mentoring students has contributed to advancements in healthcare and inspired future generations of researchers.

Legacy and Future Contributions

As a respected academic and researcher, Dr. Assanga's legacy lies in his extensive body of work, mentorship of aspiring scientists, and active participation in scientific discourse. His commitment to advancing knowledge in pharmaceutical sciences and immunology ensures that his contributions will continue to shape the field for years to come. In the future, he aims to further explore the therapeutic potential of natural products and collaborate on interdisciplinary research projects aimed at addressing pressing healthcare challenges.

Notable Publications

Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration 2022 (10)

Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass 2022 (11)

Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity 2022 (20)

Assoc Prof Dr. Nicola Micale | Pharmacology, Toxicology and Pharmaceutical Science | Best Research Award

Published on 05/01/202405/01/2024 by Book of Award

Assoc Prof Dr. Nicola Micale | Pharmacology, Toxicology and Pharmaceutical Science | Best Research Award

University of Messina | Italy

Author Profile

Scopus

Early Academic Pursuits

Associate Professor Dr. Nicola Micale commenced his academic journey with an exceptional focus on Chemistry and Pharmaceutical Technology, culminating in an honored degree from the University of Messina. This foundation laid the groundwork for his specialization in pharmacology and pharmaceutical sciences.

Professional Endeavors

Micale's career trajectory has been marked by a series of esteemed positions, from pivotal research roles to impactful lectureships across Europe. His academic pursuits have extended globally, emphasizing collaborative research ventures and immersive academic experiences.

Contributions and Research Focus

Central to Micale's contributions is his intensive focus on neurodegenerative disorders and innovative drug design. His research spans diverse areas, ranging from peptidomimetics to targeted drug development, showcasing a commitment to combatting microbial infections and malignancies.

Accolades and Recognition

Micale's exemplary research earned him notable recognition, including the Farmindustria Award for Pharmaceutical Research and invitations to deliver lectures at prestigious international conferences. These accolades affirm his expertise and contributions to the field.

Impact and Influence

Beyond his research contributions, Micale's influence is evident through his pivotal roles on the editorial boards of multiple international scientific journals. His role as a reviewer for esteemed publications underscores his commitment to shaping scholarly dialogue and validating scientific research.

Legacy and Future Contributions

Associate Professor Dr. Nicola Micale's legacy is rooted in his multidisciplinary approach to pharmaceutical sciences and his dedication to fostering global scientific collaborations. His ongoing contributions are poised to drive advancements in pharmaceutical research, leaving a lasting imprint on the field's progression and innovation.

Notable Publications

Discovery of a Novel Trifluoromethyl Diazirine Inhibitor of SARS-CoV-2 M pro 2023 (5)

Computational Design, Synthesis, and Biophysical Evaluation of β-Amido Boronic Acids as SARS-CoV-2 M pro Inhibitors 2023 (3)